Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BMA202201

CD40 mAb

BLA Filing
  • Project profile
    Project name: CD40 mAb
    Indications: Advanced solid tumors
    Research phase: Phase 1
    Cooperation demands: License-out or co-development
  • Highlights

    1. Clear MoA.

    CD40 is a cell-surface member of the TNF receptors superfamily. CD40 is extensively expressed on APC. Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and re-educate macrophages to destroy tumor stroma. anti-CD40 IgG subclass binds both activating S(hFcγRIIA) and inhibitory (hFcγRIIB) IgG receptors. Anti-CD40 can only have anti-tumor effects when it selectively binds to FcyRⅡB.

    2. Excellent preclinical efficacy:

    (1) Cross with human and rhesus monkeys, not with mouse/ rats.

    (2) No immunotoxicity: no ADCC activity, lower CDC activity than APX004M.

    no ADCC activity, lower CDC activity than APX004M

    (3) Higher tumor-killing activity and higher immune memory effect than RO7009789 and APX005M in vivo.

    no ADCC activity, lower CDC activity than APX004M

    (4) Excellent safety: MTD= 30 mg/kg in rhesus monkeys; Plasma cytokine concentrations (IFNγ, TNFα, IL6, IL1β, IL2, IL4) were not abnormally increased after mAb administration.

    3. Excellent PhaseⅠclinical result:

    (1) No DLTs or SAEs observed in the dosages tested (0.01mg/kg through 0.1mg/kg).

    (2) One patient with metastatic melanoma treated with a low dose (0.03 mg/kg) of the CD40 mAb achieved SD.

    4. Good market potential:
    It is estimated that the number of new pancreatic cancer patients worldwide will reach 486,300 in 2028, and the pancreatic cancer drug market will reach US$4.1 billion.

  • Project Introduction

    1. Asset type: CD40 mAb

    2. Indication: Advanced solid tumors

    4. Research phase: Phase 1

    5. Cooperation demands:   License-out or co-development

    6. Research progress:

    1) Completed preclinical development

    2) Phase I clinical trials were initiated to evaluate the safety, tolerability, pharmacokinetics and efficacy of candidate antibodies for advanced malignancies.

Comments (0)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message